Orchid Pharma Limited — Board Meeting, 11-11-2024: Outcome of Board Meeting

Orchid Pharma's recent board meeting approved the unaudited financial results for Q2 and the first half of FY 2024-25, reflecting a consolidated profit before tax of ₹5,472.84 lakhs. Revenue decreased to ₹48,283.98 lakhs compared to the previous year. The board also provided a statement on fund utilization from their Qualified Institutions Placement, confirming no deviations in the fund's intended purpose. Full results and details are available on their website.